

FORM PTO-1449

Att. Docket No.: REG 900A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

USSN : 10/055,842

Applicant: Gale, N.W., et al.

Date Filed: January 23, 2002

Title: Methods of Imaging and Targeting
Vasculature

Examiner: Not yet known

Group Art Unit: 1619

February 6, 2003

U.S. PATENT DOCUMENTS

<u>Examiner</u> <u>Initials</u>	<u>Patent</u> <u>Number</u>	<u>Issue</u> <u>Date</u>	<u>Publication</u> <u>Number</u>	<u>Publication</u> <u>Date</u>	<u>Name</u>
------------------------------------	--------------------------------	-----------------------------	-------------------------------------	-----------------------------------	-------------

FOREIGN PATENT DOCUMENTS

<u>Examiner</u> <u>Initials</u>	<u>Document</u> <u>Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/</u> <u>Date Subclass</u>	<u>Translation</u> <u>Yes No</u>
------------------------------------	----------------------------------	-------------	----------------	---------------------------------------	-------------------------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

_____ Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18

_____ Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125

_____ Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494

_____ Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204

_____ Wang, H.U., et al., 1998, "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell 93:741-753.

1619

RECEIVED

FEB 14 2003

TECH CENTER 1600/2900

____ Gerety, S.S., et al., 1999, "Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development", Mol Cell 4:403-414.

____ Adams, R.H., et al., 1999, "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis", Genes & Dev 13:295-306.

EXAMINER
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Linda O. Palladino

Reg. No. 45,636

Agent for Applicants

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400



Att. Dkt. No.: REG 900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
FEB 14 2003
TECH CENTER 1600/2900

Serial No.: 10/055,842 Group: 1619
Filing Date: January 23, 2002 Examiner: Unknown
Title: Method of Imaging and Targeting Vasculature

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey
Bernadette B. Fahey

February 6, 2003
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Assistant Comm. Patent and Trademarks
Washington, D.C. 20231

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [x] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

- ☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- ☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).


REQUEST FOR TRANSFER OF REFERENCE COPIES

- [] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN _____, filed _____, be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$ _____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted



Linda O. Palladino
Reg. No. 45,636
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400